Replies to post #16374 on NorthWest Biotherapeutics Inc (NWBO)

[XenaLives]

I'm not sure how easy it would be for institutions to take a big position in NWBO. It might be difficult to acquire a large number of shares with so many low volume days. But I'm not an expert AT ALL on that count. Perhaps someone else on the board can explain how an institution would establish a large position.

Instys have a catch-22. If they move in now they drive share price up just because they move in. If they wait, share price will still go up. IMO Linda and others will keep this closely held until share price appreciates enough that they can finance R&D without unreasonable dilution.

[Doktornolittle]

Revenue from Germany would certainly be a positive, but revenue from German patients covered by insurance would be a much larger positive.

Revenue from self pay patients validates NW and Linda Powers, but revenue from German DCVax-L patients that are receiving insurance reimbursement validates DCVax-L efficacy. In fact, we might be able to infer what level of efficacy the German's assessed. That would be a tell on how long until DCVax-L gets approved here in the US.